In preclinical studies, multikinase inhibitors sorafenib and linifanib induced the activation of autophagic flux, suppression of the mTOR and mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinases (ERK) signaling pathways in HCC cells, and pharmacological inhibition of autophagy enhanced cell death. Here, MAP2K7 is linked to hepatocellular carcinoma.